Medical disclaimer
Palbociclib added to maintenance therapy for HR-positive, HER2-positive metastatic breast cancer
7 min read
Prepared by Bookimed editorial team
Medical content and care coordination

The named clinic is an author affiliation. The study patients were not established as patients treated at that clinic.
Key takeaways
- Palbociclib plus maintenance HER2-targeted and endocrine therapies had a median progression-free survival of 44.3 months, compared with 29.1 months for standard therapy.
- The hazard ratio for disease progression or death was 0.75 (95% confidence interval 0.59 to 0.96).
- Grade 3 adverse events occurred in 79.7% of the palbociclib group and 30.6% of the standard-therapy group, mainly from neutropenia (a low white blood cell count).
- The trial was multicentre and the abstract does not name the treating sites, so patients were not shown to be treated at Hospital Quiron Barcelona.
- Group results do not predict what will happen for any one person.
The question this study addresses
PATINA was a phase 3, open-label, randomized multicentre trial. It enrolled 518 patients whose disease had not progressed after four to eight cycles of chemotherapy plus HER2-targeted therapy. They were assigned 1:1 to maintenance HER2-targeted and endocrine therapies with palbociclib (261 patients) or without it (257 patients). The primary end point was investigator-assessed progression-free survival. Hospital Quiron Barcelona is linked to the paper because one author lists Quirón Dexeus in Barcelona, a site in the same group and city. The abstract does not say where patients were treated.
- The situation
- Hormone-receptor-positive, HER2-positive metastatic breast cancer that had not progressed after first-line chemotherapy plus HER2-targeted therapy.
- The treatment
- Palbociclib, a drug that blocks cyclin-dependent kinases 4 and 6, added to maintenance HER2-targeted and endocrine therapies.
What this evidence cannot establish
- The abstract does not name the treating sites, and the clinic appears only as an author affiliation, so the results cannot be attributed to Hospital Quiron Barcelona.
- The trial was open-label, and progression-free survival was assessed by investigators.
- Objective response, clinical benefit and overall survival numbers are not given in the abstract.
Patient groups in the published study
261 patients · Published study group
Palbociclib added to maintenance therapy
- Indication
- Hormone-receptor-positive, HER2-positive metastatic breast cancer
- Treatment
- Palbociclib plus maintenance HER2-targeted and endocrine therapies
261 patients assigned to the palbociclib group, with a median follow-up of 53.5 months.
These patients had no disease progression after four to eight cycles of chemotherapy plus HER2-targeted therapy.
They received maintenance HER2-targeted and endocrine therapies together with palbociclib.
Median progression-free survival (median, months)
44.3 months
261 patients · Study group
median 53.5 months
Grade 3 adverse events
79.7%
261 patients · Study group
not stated
Reported risks
- Study-wide item: palbociclib increased toxic effects, mainly neutropenia. Grade 3 adverse events occurred in 79.7% of this group.
Limits of this evidence
- Treating sites are not named, and objective response, clinical benefit and overall survival numbers are not given for this group.
For a clinic assessment
- Pathology report showing hormone-receptor and HER2 status
- Records of the earlier chemotherapy and HER2-targeted therapy, including the number of cycles and the latest imaging
257 patients · Published study group
Standard maintenance therapy alone
- Indication
- Hormone-receptor-positive, HER2-positive metastatic breast cancer
- Treatment
- Standard maintenance HER2-targeted and endocrine therapies without palbociclib
257 patients assigned to standard therapy, with a median follow-up of 53.5 months.
These patients had the same disease and the same earlier treatment as the palbociclib group.
They received maintenance HER2-targeted and endocrine therapies without palbociclib. Their median progression-free survival was 29.1 months.
Median progression-free survival (median, months)
29.1 months
257 patients · Study group
median 53.5 months
Reported risks
- Study-wide item: grade 3 adverse events occurred in 30.6% of the standard-therapy group, compared with 79.7% in the palbociclib group.
Limits of this evidence
- Treating sites are not named, and objective response, clinical benefit and overall survival numbers are not given for this group.
For a clinic assessment
- Current medication list, including endocrine and HER2-targeted therapies
- Recent blood test results and oncology notes
Results and limits of the study
At a median follow-up of 53.5 months, median progression-free survival was 44.3 months with palbociclib and 29.1 months with standard therapy (hazard ratio 0.75; 95% confidence interval 0.59 to 0.96; two-sided P = 0.02). The authors report a significant improvement in progression-free survival, with increased toxic effects, mainly neutropenia.
Risks reported by the source
- Grade 3 adverse events, predominantly from neutropenia, occurred in 79.7% of patients with palbociclib and 30.6% with standard therapy.
- Grade 4 adverse events occurred in 10.0% of patients with palbociclib and 3.6% with standard therapy.
Limitations and unknowns
- Where the patients were treated is not stated.
- Objective response, clinical benefit and overall survival numbers are not given in the abstract.
- It is not known how these group results apply to an individual patient.
- The abstract does not say how long side effects lasted.
What to clarify in your treatment plan
Before booking, ask the clinic whether it offers this kind of maintenance treatment and which specialist would review your records. Ask what records it needs and how treatment and follow-up would be organized. Ask who will monitor your blood counts and how the clinic handles urgent problems.
Hospital Quiron Barcelona: clinic profile
- Hospital Quiron Barcelona appears in this research through an author affiliation: one author lists Quirón Dexeus in Barcelona, a site in the same group and city.
- The abstract does not say where patients were treated, so the page does not claim they were treated at Hospital Quiron Barcelona.
- The clinic profile is available on Bookimed.

Safety and recovery: general information
General patient guidance, provided separately from the case evidence. Follow your treating team's instructions.
Possible side effects
- Chemotherapy can cause tiredness, nausea and vomiting, a sore mouth and throat, and a weakened immune system that raises the chance of infections.
Ask your care team which of these to expect and how they would be managed.
- Some types of chemotherapy may affect fertility, either temporarily or permanently.
Raise fertility questions with your oncologist before treatment starts.
- Damage to healthy cells may cause side effects such as mouth sores, nausea and hair loss.
Ask what mouth care and other supportive measures the clinic provides.
Recovery and aftercare
- Side effects usually start a few days or weeks after treatment begins and go away after it stops, although some can last longer or start only after treatment finishes.
Ask how long the clinic follows patients after treatment ends.
- Many people can work during chemotherapy if they match their work schedule to how they feel.
Discuss your work plans with your care team.
Suitability and cautions
- Chemotherapy medicines can be very harmful for an unborn baby, so anyone who may be pregnant should tell the care team as soon as possible.
Tell the clinic about any possible pregnancy before any treatment decision.
- The treatment needed depends on the type of cancer, whether and where it has spread, and any other health problems.
Have your own oncologist review whether this approach fits your situation.
When to contact the clinic
- Contact the care team urgently for a high temperature, other signs of infection such as a sore throat, cough or pain when peeing, or swelling and warmth in a leg or arm.
Ask the clinic for an emergency contact number and clear instructions.
- Sudden breathlessness, sharp chest pain or coughing up blood also needs urgent contact.
Keep the clinic's urgent contact details with you.
Request a personal plan from the clinic
Ask Hospital Quiron Barcelona about maintenance therapy options for HR-positive, HER2-positive metastatic breast cancer
Send your medical records to the Bookimed coordinator, who will pass them to the clinic and ask whether it can review your case. The clinic decides on any treatment after its own assessment.
Ask the clinic for a current, itemized quotation. Published evidence does not establish package inclusions or a current price.
Frequently asked questions
Who ran the PATINA study and where were patients treated?
PATINA was a multicentre trial, and the abstract does not say where patients were treated. Hospital Quiron Barcelona appears only because one author lists Quirón Dexeus in Barcelona, a site in the same group and city. Patients were therefore not shown to be treated at Hospital Quiron Barcelona. The trial was funded by Pfizer and others. Bookimed did not run the study.
Did palbociclib help patients live longer without progression?
Progression-free survival was longer with palbociclib. Median progression-free survival was 44.3 months with palbociclib and 29.1 months with standard therapy, at a median follow-up of 53.5 months. The hazard ratio was 0.75 (95% confidence interval 0.59 to 0.96). These are group results and not a forecast for any individual patient.
What side effects were reported with palbociclib?
Serious side effects were more common with palbociclib, mainly neutropenia (a low white blood cell count). Grade 3 adverse events occurred in 79.7% of the palbociclib group and 30.6% of the standard-therapy group. Grade 4 events occurred in 10.0% and 3.6%. Discuss with your oncologist how blood counts would be monitored.
Who was included in the trial?
The trial enrolled 518 patients with hormone-receptor-positive, HER2-positive metastatic breast cancer. They had no disease progression after four to eight cycles of chemotherapy plus HER2-targeted therapy. 261 patients were assigned to palbociclib and 257 to standard therapy. Whether the results apply to you depends on your own medical situation, so your oncologist should review it.
Sources and scope
This page was prepared from the published abstract of the PATINA trial and its structured data, with safety information paraphrased from NHS and National Cancer Institute chemotherapy guidance. Bookimed did not run the study.
- 1. Metzger et al. – Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer.
Phase 3 open-label randomized multicentre trial · 2026
518 adults with hormone-receptor-positive, HER2-positive metastatic breast cancer without progression after first-line chemotherapy plus HER2-targeted therapy
Follow-up: Median 53.5 months
Only the abstract was used, so treating sites, response rates and overall survival numbers are not available.
- 2. NHS
- 3. National Cancer Institute
- 4. Hospital Quiron Barcelona on Bookimed
Scope and limitations
- A research summary is not an individual medical recommendation.
- Group results describe the study participants, not a forecast for any one patient.
Related procedures
About the editorial team

Prepared by
Bookimed editorial teamMedical content and care coordination
Bookimed prepares evidence summaries from published medical sources and anonymized care records. The clinic and any doctors named on this page are identified separately in their own sections.